Andrew Johns, MD
Department of Genitourinary Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2017 | Indiana University School of Medicine, Indianapolis, Indiana, US, Human Medicine, Doctor of Medicine |
| 2013 | Indiana University, Bloomington, Indiana, US, Neuroscience, Bachelor of Science |
| 2013 | Indiana University, Indianapolis, Indiana, US, French, Spanish, Bachelor of Arts |
Postgraduate Training
| 2021-2024 | Fellow & Chief Fellow, Hematology and Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2017-2021 | Resident & Chief Resident, Internal Medicine, The Ohio State University, Columbus, Ohio |
Licenses & Certifications
| 2024 | American Board of Internal Medicine, Hematology Board Certification |
| 2024 | American Board of Internal Medicine, Medical Oncology Board Certification |
| 2024 | Basic Life Support |
| 2023 | DEA Practitioner |
| 2023 | Advanced Cardiovascular Life Support Certification |
| 2022 | Texas Medical Board |
| 2022 | Certified Bilingual (Spanish) Provider |
| 2020 | American Board of Internal Medicine, Internal Medicine Board Certification |
Experience & Service
Administrative Appointments/Responsibilities
Chief Fellow for Education, Hematology and Medical Oncology Fellowship, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2023 - 2024
Chief Resident for Education and Research, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, 2020 - 2021
Intramural Institutional Committee Activities
Member, Hematology and Medical Oncology fellowship program director interview committee, The University of Texas MD Anderson Cancer Center, 2024
Member, Hematology and Medical Oncology fellowship program candidate interview committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Committee Member, Institutional Testicular Cancer Guidelines, The University of Texas MD Anderson Cancer Center
Extramural Institutional Committee Activities
Member, Genitourinary medical oncology outpatient clinical prioritization committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Member, Housestaff Education Committee, The Ohio State University Wexner Medical Center, 2017 - 2021
Alternate Representative, Housestaff Quality Forum, The Ohio State University Wexner Medical Center, 2017 - 2019
Member, Pharmacy & Therapeutics Formulary Committee, The Ohio State University Wexner Medical Center, 2017 - 2019
Member, Medical Student Activities Committee, Indiana University School of Medicine, 2015 - 2017
Member, Medical Student Technology Committee, Indiana University School of Medicine, 2015 - 2017
Student Chapter Vice President, Christian Medical and Dental Association, Indiana University School of Medicine, 2014 - 2015
Student Chapter Vice President, Christian Medical and Dental Association, Indiana University School of Medicine, 2013 - 2017
Honors & Awards
| 2024 | The Richard Theriault Humanitas Award, Hematology and Medical Oncology fellowship program, The University of Texas MD Anderson Cancer Center |
| 2023 | Conquer Cancer Foundation Merit Award, American Society of Clinical Oncology |
| 2023 | Nomination and Selection as Chief Fellow, Hematology and Medical Oncology fellowship program, The University of Texas MD Anderson Cancer Center |
| 2019 | Dr. Michael R. Grever Award for the Outstanding Clinical Resident in Hematology & Oncology, Department of Internal Medicine, The Ohio State University Wexner Medical Center |
| 2019 | Resident Travel Award, American Geriatrics Society Annual Scientific Meeting |
| 2019 | Presidential Poster Session Selection, American Geriatrics Society Annual Scientific Meeting |
| 2019 | Nomination and Selection as Chief Resident, Department of Internal Medicine, The Ohio State University Wexner Medical Center |
| 2018 | Second Place Team, Doctor’s Dilemma Competition, American College of Physicians Ohio/Air Force Chapter Scientific Meeting |
| 2018 | Third Place, Clinical Vignette Poster Presentation, American College of Physicians Ohio/Air Force Chapter Scientific Meeting |
| 2018 | “Top Ten Provider Comments of the Week”, The Ohio State University Wexner Medical Center |
| 2017 | Dr. Franklin Bryan Award for Excellence in Patient Care, Indiana University School of Medicine |
| 2015 | Professor Joel A. Vilensky Technology Grant, Indiana University School of Medicine |
| 2013 | Provost’s Award for Undergraduate Research and Creative Activity, Indiana University |
| 2012 | Phi Beta Kappa, Indiana University |
| 2012 | Grace P. Young Award, Department of French and Italian, Indiana University |
| 2009 | Herman B Wells Scholar, Indiana University |
Professional Memberships
Selected Presentations & Talks
Regional Presentations
- 2026. Management of refractory penile cancer. Invited. Christopher G. Wood Advances In Urologic Oncology Symposium. San Antonio, Texas, US.
Selected Publications
Peer-Reviewed Articles
- Thomas Z, Glover M, Johns AC, Crupi E, Lin J, Shah AY, Moussa MJ, Jiang CY, Desai M, Ward JF, Karam JA, Hofstetter WL, Choi SL, Nieto YL, Alhalabi O, Campbell MT. Utility of Circulating Tumor DNA as a Monitoring Tool for Marker-Negative Germ Cell Tumors and Somatic Type Malignancies. Clin Genitourin Cancer:102650, 2026. e-Pub 2026. PMID: 42692966.
- Thomas Z, Johns AC, Glover M, Crupi E, Nieto YL, Ward JF, Karam JA, Hofstetter WL, Desai M, Choi SL, Shah AY, Lin J, Moussa MJ, Jiang CY, Alhalabi O, Campbell MT. Divergent biology and outcomes of somatic transformations in germ cell tumors. Oncologist 31(8), 2026. e-Pub 2026. PMID: 42378441.
- Petouhoff, A, Hicks, R, Husain, M, Hoyd, R, Xu, M, Dravillas, CE, Patel, S, Johns, AC, Grogan, M, Li, M, Lopez, G, Miah, A, Liu, YZ, Muniak, M, Schmidt, M, Das, A, Lathrop, H, Das, P, Secor, A, Haddad, T, Tinoco, G, Carbone, DP, Kendra, KL, Otterson, GA, Presley, CJ, Mace, TA, Spakowicz, DJ, Owen, D. Impact of proton pump inhibitors on immunotherapy is modulated by prior chemotherapy and linked to gut microbiome–immune cell signatures. Cancer Immunology, Immunotherapy 75(4), 2026. e-Pub 2026. PMID: 41801404.
- Doshi, SD, Dizman, N, Ocejo, A, Knezevic, A, Moura Nascimento Santos, MJ, Cornish, AE, Johns, AC, Campbell, M, Kotecha, RR, Jonasch, E, Shah, NJ, Alhalabi, O, Carlo, M, Shah, AY, Feldman, DR, Msaouel, P, Motzer, RJ, Tannir, NM, Hahn, AW, Voss, MH. A multi-institution analysis of outcomes with first-line ipilimumab and nivolumab for 514 patients with metastatic clear cell renal cell carcinoma by number of doses. Journal of Clinical Oncology 44:441, 2026. e-Pub 2026.
- Grewal K, Moura Nascimento Santos MJ, Chauhan PK, Yu K, Tannir NM, Mukhida SS, Venkatesh N, Shah AY, Zurita AJ, Johns AC, Campbell MT, Goswami S, Gao J, Jonasch E, McQuade JL, Alhalabi O, Msaouel P, Hahn AW. Influence of body composition on the efficacy of nivolumab plus ipilimumab for metastatic clear cell renal cell carcinoma. Journal for immunotherapy of cancer 14(3), 2026. e-Pub 2026. PMID: 41775432.
- Ocejo, A, Dizman, N, Doshi, SD, Knezevic, A, Moura Nascimento Santos, MJ, Cornish, AE, Johns, AC, Campbell, M, Kotecha, RR, Jonasch, E, Shah, NJ, Alhalabi, O, Carlo, M, Shah, AY, Feldman, DR, Msaouel, P, Tannir, NM, Motzer, RJ, Hahn, AW, Voss, MH. Clinical outcomes and tolerability of ipilimumab/nivolumab in older (≥70 years) versus younger patients with metastatic clear cell RCC. Journal of Clinical Oncology 44:444, 2026. e-Pub 2026.
- Wang, J, Johns, AC, Alhalabi, O, Gao, J, Goswami, S, Hahn, AW, Jonasch, E, Campbell, M, Desai, M, Lin, JK, Msaouel, P, Shah, AY, Zurita-Saavedra, A, Tannir, NM. A phase II trial of nivolumab, ipilimumab and cabozantinib in patients with brain metastases from renal cell carcinoma. Journal of Clinical Oncology 44:492, 2026. e-Pub 2026.
- Dizman, N, Tidwell, R, Sheth, RA, Alhalabi, O, Corn, P, Campbell, M, Goswami, S, Johns, AC, Jonasch, E, Lin, JK, Shah, AY, Wang, J, Zurita-Saavedra, A, Gao, J, Tannir, NM, Hahn, AW, Msaouel, P. Ivonescimab in metastatic clear cell renal cell carcinoma (mccRCC) after immune checkpoint inhibitor therapy. Journal of Clinical Oncology 44:TPS573-TPS573, 2026. e-Pub 2026.
- Thomas, Z, Glover, M, Johns, AC, Moussa, MJ, Crupi, E, Lin, JK, Ward, JF, Karam, JA, Hofstetter, WL, Choi, S, Nieto, Y, Desai, M, Shah, AY, Jiang, CY, Alhalabi, O, Campbell, M. Circulating tumor DNA (ctDNA) as a real-time biomarker in marker-negative germ cell tumors (GCT). Journal of Clinical Oncology 44:619, 2026. e-Pub 2026.
- Hatoum F, Souza GR, Johnson J, Miller J, Fazili A, Pettaway CA, Campbell MT, Neubauer R, Johns A, Mizelle SR, Kim Y, Chadha J, Zhang J, Jameel G, Oschmann E, Dhillon J, Moscu A, Janeway R, Harris W, Lu X, Spiess PE, Chahoud J. Phase 2 study of dostarlimab plus niraparib in stage III-IV recurrent or refractory Penile squamous cell carcinoma. Future Oncol 21(28):3619-3627, 2025. e-Pub 2025. PMID: 41163621.
- Jackson JC, Johns AC, Campos Clemente L, Manuel CM, Qiao W, Lu W, Khan K, Solis Soto LM, Chahoud J, Rao P, Campbell MT, Pettaway CA, Zacharias NM. Tissue Factor Expression in Penile Squamous Cell Carcinoma: A Potential Marker of HPV-Independent Disease. Cancers (Basel) 17(21), 2025. e-Pub 2025. PMID: 41228204.
- Grippin AJ, Marconi C, Copling S, Li N, Braun C, Woody C, Young E, Gupta P, Wang M, Wu A, Jeong SD, Soni D, Weidert F, Xie C, Goldenberg E, Kim A, Zhao C, DeVries A, Castillo P, Lohray R, Rooney MK, Schrank BR, Wang Y, Ma Y, Chang E, Kouzy R, Dyson K, Jafarnia J, Nariman N, Gladish G, New J, Argueta A, Amaya D, Thomas N, Doty A, Chen J, Copling N, Alatrash G, Simon J, Davies AB, Dennis W, Liang R, Lewis J, Wei X, Rinsurongkawong W, Vaporciyan AA, Johns A, Lee J, Lee JH, Sun R, Sharma P, Tran H, Zhang J, Gibbons DL, Wargo J, Kim BYS, Heymach JV, Mendez-Gomez HR, Jiang W, Sayour EJ, Lin SH. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature 647(8089):488-497, 2025. e-Pub 2025. PMID: 41125896.
- Nieto Y, Ward JF, Hofstetter W, Rice D, Karam JA, Pisters L, Vauthey JN, Shah A, Lin JK, Johns AC, Araujo J, Tu SM, Wang J, Li J, Abudayyeh A, Thall PF, Bassett R, Barnett M, Gulbis A, Shigle TL, Ramdial J, Popat U, Qazilbash M, Jones RB, Andersson BS, Shpall EJ, Sheikh I, Pagliaro L, Campbell MT. HIGH-DOSE CHEMOTHERAPY FOR MULTIPLY OR POOR-RISK RELAPSED GERM-CELL TUMORS. Clin Cancer Res 32(2):300-311, 2025. e-Pub 2025. PMID: 40853903.
- Jackson JC, Sanchez D, Joon AY, Estecio MR, Johns AC, Shah AY, Campbell M, Ward JF, Pisters LL, Guo CC, Zhang M, Zacharias NM, Tu SM. Bilateral Germ Cell Tumor of the Testis: Biological and Clinical Implications for a Stem Versus Genetic Origin of Cancers. Cells 14(9), 2025. e-Pub 2025. PMID: 40358182.
- Moussa MJ, Khandelwal J, Wilson NR, Malikayil KL, Surasi DS, Bathala TK, Lin Y, Rao P, Tamboli P, Sircar K, Ajufo H, Elsayes KM, Shah A, Johns AC, Goswami S, Hasanov E, Jonasch E, Msaouel P, Campbell MT, Alhalabi O, Tannir NM. Efficacy and safety of nivolumab plus ipilimumab in patients with metastatic variant histology (non-clear cell) renal cell carcinoma. J Immunother Cancer 13(2), 2025. e-Pub 2025. PMID: 39939142.
- Wang E, Rupe ES, Mukhida SS, Johns AC, Campbell MT, Shah AY, Zurita AJ, Gao J, Goswami S, Jonasch E, Msaouel P, Tannir NM, Hahn AW. Belzutifan Efficacy and Tolerability in Patients with Sporadic Metastatic Clear Cell Renal Cell Carcinoma. Eur Urol Focus 11(1):150-158, 2024. e-Pub 2024. PMID: 39307587.
- Jackson JC, Sanchez D, Johns AC, Campbell MT, Aydin AM, Gokden N, Maraboyina S, Muesse JL, Ward JF, Pisters LL, Zacharias NM, Guo CC, Tu SM. Germ Cell Tumor of the Testis: Lethal Subtypes of a Curable Cancer. J Clin Med 13(12), 2024. e-Pub 2024. PMID: 38929965.
- Johns AC, Campbell MT, Gao M, Hahn AW, Lim Z, Wang E, Gao J, Shah AY, Msaouel P, Tannir NM. Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma. Oncologist, 2024. e-Pub 2024. PMID: 38478923.
- Johns, AC, Campbell, M, Gao, M, Lim, ZD, Wang, E, Hahn, AW, Gao, J, Shah, AY, Msaouel, P, Tannir, NM. Efficacy, safety, and tolerability of tivozanib (TIVO) in heavily pretreated patients (pts) with advanced clear-cell renal cell carcinoma (ccRCC). Journal of Clinical Oncology 42(4), 2024. e-Pub 2024.
- Haro-Silerio, JI, Johns, AC, Moussa, MJ, Wang, M, Wang, E, Kovitz, CA, Campbell, M, Jonasch, E, Shah, AY, Tannir, NM. Outcomes of patients (pts) with advanced renal cell carcinoma (aRCC) treated with cabozantinib (CABO) after lenvatinib plus pembrolizumab (LEN+PEM). Journal of Clinical Oncology 42(4), 2024. e-Pub 2024.
- Johns AC, Yang M, Wei L, Grogan M, Spakowicz D, Patel SH, Li M, Husain M, Kendra KL, Otterson GA, Rosko AE, Andersen BL, Carbone DP, Owen DH, Presley CJ. Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer. Oncologist 28(8):e625-e632, 2023. e-Pub 2023. PMID: 37085156.
- Johns AC, Yang M, Wei L, Grogan M, Patel SH, Li M, Husain M, Kendra KL, Otterson GA, Burkart JT, Spakowicz D, Hoyd R, Owen DH, Presley CJ. Association of medical comorbidities and cardiovascular disease with toxicity and survival among patients receiving checkpoint inhibitor immunotherapy. Cancer Immunol Immunother 72(7):2005-2013, 2023. e-Pub 2023. PMID: 36738310.
- Guo Y, Wei L, Patel SH, Lopez G, Grogan M, Li M, Haddad T, Johns A, Ganesan LP, Yang Y, Spakowicz DJ, Shields PG, He K, Bertino EM, Otterson GA, Carbone DP, Presley C, Kulp SK, Mace TA, Coss CC, Phelps MA, Owen DH. Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy. Clin Lung Cancer 23(4):345-355, 2022. e-Pub 2022. PMID: 35131184.
- Haddad TC, Zhao S, Li M, Patel SH, Johns A, Grogan M, Lopez G, Miah A, Wei L, Tinoco G, Riesenberg B, Li Z, Meara A, Bertino EM, Kendra K, Otterson G, Presley CJ, Owen DH. Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival. Cancer Immunol Immunother 71(5):1157-1165, 2022. e-Pub 2022. PMID: 34618180.
- Nashed A, Zhang S, Chiang CW, Zitu M, Otterson GA, Presley CJ, Kendra K, Patel SH, Johns A, Li M, Grogan M, Lopez G, Owen DH, Li L. Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events. Cancer Immunol Immunother 70(10):2761-2769, 2021. e-Pub 2021. PMID: 33625533.
- Johns AC, Wei L, Grogan M, Hoyd R, Bridges JFP, Patel SH, Li M, Husain M, Kendra KL, Otterson GA, Burkart JT, Rosko AE, Andersen BL, Carbone DP, Owen DH, Spakowicz DJ, Presley CJ. Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer. J Geriatr Oncol 12(5):813-819, 2021. e-Pub 2021. PMID: 33627226.
- Qin A, Zhao S, Miah A, Wei L, Patel S, Johns A, Grogan M, Bertino EM, He K, Shields PG, Kalemkerian GP, Gadgeel SM, Ramnath N, Schneider BJ, Hassan KA, Szerlip N, Chopra Z, Journey S, Waninger J, Spakowicz D, Carbone DP, Presley CJ, Otterson GA, Green MD, Owen DH. Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. J Natl Compr Canc Netw 19(8):915-921, 2021. e-Pub 2021. PMID: 33878726.
- Li M, Spakowicz D, Zhao S, Patel SH, Johns A, Grogan M, Miah A, Husain M, He K, Bertino EM, Shields PG, Wei L, Carbone DP, Otterson GA, Presley CJ, Owen DH. Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer. Cancer Immunol Immunother 69(11):2403-2408, 2020. e-Pub 2020. PMID: 32728772.
- Johns AC, Sorenson C, Rogers A, Agne JL, D'Souza DM, Das JK, Issa M, Perna G, Williams TM, Meara A, Kitchin T, Haglund KE, Owen DH. Clinical Course of Hypertrophic Pulmonary Osteoarthropathy in a Patient Receiving Immune Checkpoint Inhibitor Therapy. Clin Lung Cancer 21(4):e243-e245, 2020. e-Pub 2020. PMID: 32067849.
- Spakowicz D, Hoyd R, Muniak M, Husain M, Bassett JS, Wang L, Tinoco G, Patel SH, Burkart J, Miah A, Li M, Johns A, Grogan M, Carbone DP, Verschraegen CF, Kendra KL, Otterson GA, Li L, Presley CJ, Owen DH. Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications. BMC Cancer 20(1):383, 2020. e-Pub 2020. PMID: 32375706.
Review Articles
- Miah A, Tinoco G, Zhao S, Wei L, Johns A, Patel S, Li M, Grogan M, Lopez G, Husain M, Hoyd R, Mumtaz K, Meara A, Bertino EM, Kendra K, Spakowicz D, Otterson GA, Presley CJ, Owen DH. Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival. J Cancer Res Clin Oncol 149(5):2235-2242, 2023. e-Pub 2023. PMID: 36070148.
- Johns AC, Campbell MT. Toxicities From Antibody-Drug Conjugates. Cancer J 28(6):469-478, 2022. e-Pub 2022. PMID: 36383910.
- Dempsey JL, Johns A, Rosko AE, Lazarus HM. The pharmacologic management of multiple myeloma in older adults. Expert Opin Pharmacother 20(7):887-902, 2019. e-Pub 2019. PMID: 30785310.
Editorials
- Thomas Z, Pettaway CA, Alhalabi O, Campbell MT, Johns AC. Front-line chemo-immunotherapy for advanced penile cancer: ready for prime time?. Br J Cancer, 2026. PMID: 42337045.
Abstracts
- Johns, AC, Lin, R, Johnson, L, Zhao, J, Wang, W, Jonasch, E, Campbell, M, Shah, AY, Zurita-Saavedra, A, Hahn, AW, Tannir, NM, Desai, M, Lin, JK, Marin, D, Basar, R, Daher, M, Shpall, E, Rezvani, K, Msaouel, P. TANKeR-70 44:TPS571-TPS571, 2026. e-Pub 2026.
- Johns A. TANKeR-70: TGFβ-receptor type 2 knockout Allogeneic NK cells for Renal cell carcinoma expressing CD70. ASCO Genitourinary Cancers Symposium 2026.
Patient Reviews
CV information above last modified September 04, 2026